Immunovant Inc

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

ACM Research

Celsius Holdings

Crocs

Fluor

ImmunoGen

Uranium Energy

As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.

7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024

The beginning of earnings season is a good time to look at stocks that analysts are upgrading. For growth-oriented investors, that may mean looking at some of the top-rated Russell 2000 stocks.

3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024

Amgen

argenx

BeiGene

CRISPR Therapeutics

Biotech has been out of favor among investors for over two years. The sector could be on the verge of a trend reversal because of multiple tailwinds.

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

Burford Capital Limited

Liquidia Technologies Inc

Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech company serving the cannabis industry, and predicts its growth potential in the coming years.

Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am ET.

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.

Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data

Immunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall.

Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off

NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves' disease meaningfully exceeded 50% response rates.

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Arvinas Inc

Academy Sports and Outdoors

Boot Barn Hlds

CymaBay Therapeutics

Flywire Corp

Guardant Health Inc

Privia Health Group

Rocket Pharma

Viridian Therapeutics

Wall Street's best small-cap stocks to buy include pharma, biotech and specialty retail names.

Best Small-Cap Stocks to Buy for 2024 and Beyond

Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.

Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data

NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) --  Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced initial data from 600 mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults. The results show that four subcutaneously administered doses of 600 mg produced a mean IgG reduction similar to high dose batoclimab, but with minimal changes in albumin and LDL-C similar to those in placebo, confirming the potential of IMVT-1402 as a best-in-class neonatal fragment crystallizable receptor (FcRn) inhibitor.

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Immunovant continues to show promising developments in anti-FcRn platform's clinical trials and has a strong financial position. Key upcoming catalysts, including Phase 1 data and Phase 2 results, could significantly impact the company's valuation and future trajectory. Immunovant's financial stability and strategic market positioning support a buy rating, with the potential for significant market penetration and revenue generation.

Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in fireside chats at the following investor conferences:

Immunovant to Present at Upcoming Investor Conferences

Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal second quarter ended September 30, 2023.

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of 8,475,500 shares of its common stock at a price of $38.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,105,500 additional shares of common stock. Concurrent with the public offering, Immunovant sold 4,473,684 shares of common stock to Roivant Sciences, Ltd. at a price of $38.00 per share in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, or the Securities Act. The aggregate gross proceeds to Immunovant from the public offering and concurrent private placement were approximately $492.1 million, before deducting underwriting discounts and commissions, placement agent fees and offering expenses payable by Immunovant.

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions. All of the shares are to be sold by Immunovant.

Immunovant Announces Pricing of $450 Million Common Stock Financing

Tuesday, Immunovant announced early-stage trial results for an autoimmune disease candidate that caused its shares to rocket higher. Investors are bidding up the stock again today, presumably due to its prospects as a takeover target.

Why Immunovant Stock Is Bolting Higher Today

Immunovant stock surged again Wednesday after the company announced a $300 million offering on the heels of promising test results.

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering

Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.

Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data

Although Immunovant's stock has rallied around 100% since January, recent data on its therapeutic candidate, IMVT-1402, has further bolstered confidence, and we expect more upside from here. IMVT-1402's proposed subcutaneous route of administration allows for patient self-administration, potentially reducing healthcare costs and improving compliance. IMVT-1402 has shown deep IgG reductions and a potentially favorable safety profile, positioning it as a major challenger to competitors in the FcRn inhibitor class.

Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the commencement of a proposed underwritten public offering and concurrent private placement of an aggregate of $300,000,000 of shares of its common stock. Immunovant intends to offer and sell $130,000,000 of shares of its common stock in an underwritten public offering. In addition, Immunovant intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $19,500,000 of shares of its common stock offered at the public offering price. All of the shares are being offered by Immunovant.

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Immunovant (IMVT) shares virtually doubled on Tuesday after the biopharmaceutical company reported positive results from a Phase 1 trial of its experimental autoimmune disease treatment.

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

Immunovant reported positive phase 1 trial data for IMVT-1402. The company said the therapy showed a strong safety profile and fewer side effects than batoclimab.

Why Shares of Immunovant Are Soaring on Tuesday

Immunovant's IMVT-1402 shows early promise with dose-dependent IgG reduction and a decent safety profile, rejuvenating the company's drug pipeline. Despite a solid 20.9-month cash runway, escalating R&D expenses and liquidity concerns necessitate vigilant financial monitoring. Investment recommendation on IMVT stock: Shift from "Strong Sell" to "Hold," given the nascent promise in IMVT-1402 and remaining uncertainties in batoclimab and financials.

Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)

News for Immunovant Inc Stock (IMVT)